Bladder cancer treatment depends mainly on whether the cancer has grown into the muscle layer of the bladder wall.

• Non-muscle-invasive bladder cancer (NMIBC) is treated by removing the tumour through the urethra (TURBT). This is often followed by medicine placed directly into the bladder, such as BCG or chemotherapy, and regular check cystoscopies.
• Muscle-invasive bladder cancer (MIBC) usually needs chemotherapy with immunotherapy, followed by removal of the bladder (radical cystectomy). For selected patients, bladder-sparing chemoradiotherapy is an alternative.
• Advanced or metastatic bladder cancer is now usually treated first with enfortumab vedotin plus pembrolizumab. In a major trial, this combination roughly doubled median survival compared with chemotherapy.

Germany has certified bladder cancer centres (Harnblasenkrebszentren) accredited by the German Cancer Society (DKG). The EU approved several new treatments between 2024 and 2026.

Estimated prices for radical cystectomy with urinary reconstruction in Germany are around €36,000 to €41,000.

This guide explains each stage of treatment, what care in Germany involves, estimated costs and how to prepare.

What Is Bladder Cancer?

The bladder is a hollow, muscular organ in the lower abdomen that stores urine before it leaves the body. Bladder cancer is a type of cancer that develops when abnormal cells in the bladder begin to grow uncontrollably.

Types and Stages of Bladder Cancer

Most bladder cancers are urothelial carcinomas, which start in the cells lining the bladder. Rarer types include squamous cell carcinoma and adenocarcinoma, which are treated differently.

Carcinoma in situ (CIS) is a flat, high-grade cancer of the bladder lining. It needs treatment even though it has not invaded deeper.

Symptoms. The most common symptom is blood in the urine, often painless. Others include needing to pass urine often or urgently, and burning. Any visible blood in the urine should be investigated.

How Is Bladder Cancer Diagnosed and Staged?

• Cystoscopy. A thin camera is passed into the bladder. Blue-light (fluorescence) cystoscopy can help show flat lesions such as CIS.
• TURBT (transurethral resection of bladder tumour). The tumour is removed through the urethra for diagnosis and treatment. The sample must include bladder muscle so the pathologist can tell whether the cancer is muscle-invasive. A second TURBT is often recommended for high-risk T1 tumours.
• Urine cytology. Checks urine for cancer cells.
• CT urography. Examines the kidneys and ureters, which can also develop urothelial cancer.
• CT or MRI of the chest, abdomen and pelvis. Used for staging when the cancer is muscle-invasive or high-risk.
• Molecular testing in advanced disease. For example, testing for FGFR3 changes, which can make a patient eligible for targeted therapy.

Treatment plans are discussed at a multidisciplinary tumour board of urologists, medical and radiation oncologists, pathologists and radiologists.

Treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC)

TURBT removes the visible tumour. What follows depends on the risk of the cancer coming back or progressing.

• Low risk. A single dose of chemotherapy is placed in the bladder soon after TURBT, then surveillance cystoscopies.
• Intermediate risk. A course of bladder instillations with chemotherapy or BCG.
• High risk, such as high-grade T1 or CIS. BCG immunotherapy: a weakened bacterium is placed in the bladder to stimulate the immune system. There is a six-week induction course, followed by maintenance treatments for one to three years.
• Very high risk, or BCG-unresponsive disease. Radical cystectomy is often recommended. Newer bladder-sparing options include:

- Anktiva (nogapendekin alfa inbakicept) with BCG, which received conditional EU authorisation in February 2026 for BCG-unresponsive NMIBC with carcinoma in situ

- clinical trials of other intravesical treatments

- in some cases, hyperthermic or device-assisted intravesical chemotherapy, where available

Surveillance is essential. NMIBC often recurs, so regular cystoscopies continue for years. International patients can usually have these at home, following a plan from the German team.

Practical point for travellers. BCG is given weekly for six weeks, then in maintenance courses over months to years. Many international patients have TURBT and staging in Germany, then continue BCG at home if it is available there.

Treatment for Muscle-Invasive Bladder Cancer (MIBC)

Chemotherapy and immunotherapy before and after surgery

For patients fit for cisplatin, the standard is gemcitabine and cisplatin chemotherapy before surgery. In the EU, durvalumab can now be added before surgery and continued alone afterwards, following the NIAGARA trial (approved July 2025). In NIAGARA:

• the risk of the cancer returning, progressing or causing death fell by 32%
• two-year survival was 82.2% vs 75.2% with chemotherapy alone

For patients not fit for cisplatin, the EU approved enfortumab vedotin plus pembrolizumab before and after surgery in June 2026, based on the KEYNOTE-905/EV-303 trial against surgery alone:

• two-year event-free survival was 74.7% vs 39.4%
• two-year overall survival was 79.7% vs 63.1%
• 57.1% of patients had no cancer left in the bladder at surgery

Radical cystectomy

Radical cystectomy removes the bladder and nearby lymph nodes. In men, it usually includes the prostate and seminal vesicles. In women, it often includes the uterus and part of the vagina, depending on the case.

It can be done as open surgery or robot-assisted surgery. Cancer outcomes are broadly similar. Robotic surgery may mean less blood loss, but the surgeon's experience matters more than the technique.

Urinary diversion (reconstruction)

After cystectomy, urine needs a new route out of the body.

• Ileal conduit. Urine drains through a short piece of bowel to an opening (stoma) on the abdomen, into a bag. It is the simplest and most common option.
• Neobladder. A new bladder is made from bowel and connected to the urethra, so the patient passes urine as usual. It suits selected patients. It requires good kidney function and motivation for bladder training, and it can involve nighttime incontinence.
• Continent pouch. An internal reservoir that is emptied with a catheter through a small opening.

Bladder-sparing trimodality therapy (TMT)

In selected patients, the bladder can be kept by combining three treatments:

1. a thorough TURBT
2. radiotherapy
3. chemotherapy given alongside it

TMT suits patients with single tumours, no CIS, no kidney blockage, and good bladder function. Close follow-up with cystoscopies is essential. Cystectomy is still possible if the cancer returns.

Treatment for Advanced or Metastatic Bladder Cancer

First-line treatment is now enfortumab vedotin plus pembrolizumab for most patients. In the EV-302 trial, this combination was compared with platinum chemotherapy:

• median overall survival was 31.5 months vs 16.1 months
• median progression-free survival was 12.5 months vs 6.3 months

The EU approved it in August 2024.

Other options depend on fitness, previous treatment and tumour biology:

• platinum-based chemotherapy, followed by maintenance avelumab in patients whose cancer has not progressed
• immunotherapy
• erdafitinib, a targeted tablet for tumours with FGFR3 changes after previous treatment
• clinical trials

Palliative radiotherapy can control bleeding or pain.

Unproven Treatments: A Warning

Some clinics and websites promote dendritic cell "vaccines" or other cell therapies for bladder cancer, sometimes costing tens of thousands of euros. These are not approved standard treatments for bladder cancer.

The European Medicines Agency has warned that unregulated cell therapies are being sold to patients across Europe with little or no evidence of benefit and possible risks. If you are offered such a treatment, ask whether it is:

• EMA-approved
• part of a registered clinical trial
• supported by published trial results

What Treatment in Germany Involves for International Patients?

Certified bladder cancer centres

The German Cancer Society (DKG) certifies bladder cancer centres (Harnblasenkrebszentren), usually within wider uro-oncology centres. Certified centres are networks where all specialities treating a cancer work closely together. They must show in an annual audit that they meet the requirements for the specific tumour type.

The OncoMap directory lists certified centres. For cystectomy, a certified centre with experienced surgeons is strongly recommended.

Typical time in Germany

Many international patients split treatment. For example, they have chemotherapy at home, travel for cystectomy, and do follow-up cystoscopies locally. Discuss this before travelling.

Hospitals for Bladder Cancer Treatment in Germany

Check whether a hospital has:

• DKG certification as a bladder cancer centre
• surgeons who regularly perform radical cystectomy, and the type of urinary diversion you prefer
• blue-light cystoscopy and access to BCG and newer intravesical treatments
• radiotherapy for bladder-sparing treatment
• access to current systemic therapies and clinical trials
• stoma nursing and continence support
• an international patient office that can provide written estimates and interpreters

The hospitals below are examples with verified information. This is not a ranking or endorsement.

Certifications, specialists and international services change. Vaidam can confirm current details for the hospitals you are considering.

Cost of Bladder Cancer Treatment in Germany

No single fixed price applies. Cost depends on the stage, treatment plan, length of stay and hospital. Estimated prices for radical cystectomy with urinary reconstruction in Germany are around €36,000 to €41,000.

What affects the total cost?

How International Patients Can Prepare?

Medical documents to gather

• TURBT pathology report, including whether muscle was present in the sample and whether it was invaded.
• Tissue blocks or slides. German pathologists often review these.
• Cystoscopy reports.
• CT urography and staging CT or MRI (images on disc or download link, not just reports).
• Blood tests, including kidney function, which affects chemotherapy and urinary diversion choices.
• Previous treatment records: BCG or chemotherapy instillations (dates, number of doses) and any systemic therapy.
• Current medications and other medical conditions, including heart disease, diabetes and previous abdominal surgery.

Reports in languages other than English or German may need translation.

Travel and administrative documents

Visa. Most non-EU patients need a visa for medical treatment. A national (D-type) visa may be needed for longer stays. Applications usually need the hospital's invitation letter with a cost estimate, proof of funds and health insurance.

Other items to arrange:

• proof of funds or an insurer's guarantee of payment
• accommodation near the hospital for recovery after discharge
• a companion, particularly after cystectomy
• stoma or catheter supplies and training before returning home

Questions to Ask Your Urologist

1. Is my cancer muscle-invasive, and was muscle present in the TURBT sample?
2. What is my risk category if my cancer is non-muscle-invasive?
3. Do I need BCG, and can I continue it at home?
4. Am I a candidate for bladder-sparing trimodality therapy?
5. Am I fit for cisplatin? Do you recommend durvalumab or enfortumab vedotin with pembrolizumab around surgery?
6. Which urinary diversion do you recommend for me, and why?
7. Will surgery be open or robotic, and how many cystectomies does your team perform each year?
8. Is your centre DKG-certified for bladder cancer?
9. How long will I need to stay in Germany?
10. What follow-up cystoscopies and scans will I need, and where?

Recovery and Follow-Up

After TURBT. Recovery is usually quick. Blood in the urine and bladder irritation are common for a few days. A catheter may be needed briefly.

After BCG. Bladder irritation, frequent urination and flu-like symptoms for a day or two are common. Report fever that lasts more than 48 hours.

After radical cystectomy:

• Recovery takes several weeks to a few months.
• Bowel function returns gradually.
• Stoma nurses teach care of an ileal conduit.
• Neobladder patients learn to empty the new bladder on a schedule. Continence usually improves over months.
• Sexual function can be affected. Nerve-sparing techniques, rehabilitation and treatment options should be discussed before surgery.

Long-term follow-up includes:

• cystoscopies for bladder-sparing treatment or NMIBC
• CT scans
• kidney function tests
• vitamin B12 checks, after bowel is used for diversion

Outlook

Outlook depends mainly on stage at diagnosis. The figures below are US data from the American Cancer Society, based on people diagnosed between 2015 and 2021.

Source: American Cancer Society, 5-year relative survival from SEER data for people diagnosed 2015–2021.

How to read these figures:

• They are averages for large groups and cannot predict an individual outcome.
• They predate newer treatments, such as enfortumab vedotin with pembrolizumab and perioperative immunotherapy, which have improved survival in trials.
• They are not specific to treatment in Germany.

How Vaidam Helps International Patients?

Vaidam Health is a medical travel facilitation service. It does not provide medical treatment itself. When you contact Vaidam, you are assigned a case manager who can:

• share your records with partner hospitals and urologists in Germany
• obtain a medical opinion and written cost estimate, usually within 48 hours
• help you compare hospitals against the criteria above
• help with visa documentation and the hospital's invitation letter
• arrange accommodation near the hospital, airport transfers and appointment scheduling
• arrange interpreters (in Germany, interpreter services are chargeable)
• stay in contact after you return home to help with follow-up consultations and reports

Vaidam states that its services are free for patients and do not increase the hospital bill. Treatment decisions remain with your doctors.

Frequently Asked Questions

1. How much does bladder cancer treatment cost in Germany?

It depends on the stage and treatment. Estimated prices for radical cystectomy with urinary reconstruction are about €36,000 to €41,000. Diagnostic work-up can be up to about €4,570. Systemic therapies such as immunotherapy add significantly if given in Germany.

2. Will I need my bladder removed?

Not usually for non-muscle-invasive cancer, which is treated with TURBT and bladder instillations. For muscle-invasive cancer, radical cystectomy is standard. Bladder-sparing trimodality therapy is an alternative for selected patients.

3. What is BCG treatment?

BCG is an immunotherapy placed directly into the bladder through a catheter. It is used for high-risk non-muscle-invasive cancer. There is a six-week induction course, followed by maintenance treatments for one to three years.

4. Is robotic cystectomy better than open surgery?

Cancer outcomes are broadly similar. Robotic surgery may reduce blood loss. The surgeon's experience and the centre's volume matter more than the technique.

5. Can I have a new bladder (neobladder)?

Some patients can. It depends on kidney function, the extent of the cancer, general health and willingness to do bladder training. Otherwise, an ileal conduit with a stoma is used.

6. What is the newest treatment for advanced bladder cancer?

Enfortumab vedotin plus pembrolizumab, approved in the EU in August 2024 for first-line treatment. In the EV-302 trial, median survival was 31.5 months compared with 16.1 months with chemotherapy.

7. Is immunotherapy used before bladder surgery?

Yes, for eligible patients. In the EU, durvalumab can be added to chemotherapy before and after surgery for cisplatin-fit patients (approved July 2025). Enfortumab vedotin with pembrolizumab can be used around surgery for patients who cannot have cisplatin (approved June 2026).

8. Is dendritic cell therapy an option for bladder cancer?

It is not an approved standard treatment for bladder cancer. The European Medicines Agency has warned about unregulated cell therapies being sold in Europe. Ask whether any treatment offered is EMA-approved or part of a registered clinical trial.

9. How long will I need to stay in Germany?

About one to two weeks for TURBT and staging, and around two to three weeks or more for radical cystectomy. Chemotherapy and BCG courses are often completed at home under a plan agreed with the German team.

10. Can I get a second opinion from Germany before travelling?

Yes. German centres can review your TURBT pathology, scans and treatment history remotely. Sending tissue blocks allows German pathologists to confirm the stage.

Sources

• AstraZeneca: Imfinzi approved in the EU for muscle-invasive bladder cancer (4 July 2025), NIAGARA results.
• Astellas: European Commission approves Padcev with Keytruda for first-line advanced urothelial cancer (28 August 2024), EV-302 results.
• Urology Times: European Commission approves perioperative enfortumab vedotin with pembrolizumab for cisplatin-ineligible MIBC (24 June 2026), KEYNOTE-905/EV-303 results.
• Urology Times: nogapendekin alfa inbakicept (Anktiva) receives EU conditional authorisation for BCG-unresponsive NMIBC with CIS (18 February 2026).
• Pharmaceutical Technology: EMA warning on unregulated cell therapies, including dendritic cell therapies, sold in Europe.
• American Cancer Society: Bladder cancer survival rates (SEER 2015–2021).
• OnkoZert: Uroonkologische Zentren (bladder). UKGM Giessen certified bladder cancer centre page.
• Heidelberg University Hospital urology: bladder conditions page. Charité urology: bladder cancer page.
• EAU guidelines on non-muscle-invasive and muscle-invasive bladder cancer (general treatment framework).
• Vaidam.com homepage (service descriptions).